Introduction
Quinolone resistance in Staphylococcus aureus isolates involves mutations within the grl and gyr gene loci. 1 In addition, multi-drug efflux transporters like NorA seem to confer lower susceptibility to fluoroquinolones. [2] [3] [4] The efflux of fluoroquinolones from the cell mostly results in a lower level of resistance than that seen in grlA or gyrA mutants. 4 Since most experiments concerning NorA in S. aureus have only used one clinical fluoroquinolonesusceptible strain, S. aureus SA1199, 2, 5 it is possible that efflux pumps are important only in a limited number of fluoroquinolone-susceptible and -resistant S. aureus isolates. The degree of transporter activity in a panel of clinical fluoroquinolone-susceptible and -resistant S. aureus isolates has not been investigated. The plant alkaloid reserpine has been shown to inhibit multidrug transporters like NorA, 3 increasing the intracellular concentration of fluoroquinolones, thus potentially lowering MICs.
To analyse the effect of reserpine and the subsequent inhibition of efflux pumps, such as NorA, on the susceptibility to three fluoroquinolones, the MICs and IC 50 s were determined for 102 clonally non-related S. aureus strains from eight countries to ciprofloxacin, sparfloxacin and moxifloxacin, in the presence or absence of reserpine.
Values obtained were correlated with characterized mutations in the norA, gyrA, gyrB, grlA and grlB gene loci. Furthermore, we investigated the stability of the norA, gyrA, gyrB, grlA and grlB gene loci, as well as efflux transporter activity in 25 related MRSA isolates belonging to a clone (MRSA type-1) determined by pulsed-field gel electrophoresis (PFGE).
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Materials and methods
Bacterial isolates
One hundred and two clinical S. aureus isolates (84 methicillin-resistant and 18 methicillin-susceptible, 66 ciprofloxacin-resistant and 36 ciprofloxacin-susceptible) were included in this study. Sixty-six S. aureus isolates from patients residing in Germany and 36 S. aureus isolates from seven other countries were tested. 6 In a previous manuscript the presence of mutations within grlA, grlB, gyrA or gyrB in these 102 isolates and the corresponding MICs of different fluoroquinolones have been characterized in detail. 7 Additionally, 25 MRSA type-1 isolates from the Düsseldorf area over a period of 3 years 7 were included in the study in order to analyse the stability of the gene loci involved in quinolone resistance, as well as the effect of reserpine.
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The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus 
Antimicrobial agents and MIC and IC 50 determinations
Ciprofloxacin and reserpine were purchased from Sigma Chemical Co. (St Louis, MO, USA), whereas sparfloxacin (Rhône-Poulenc Rorer, Vitry sur Seine, France) and moxifloxacin (Bayer, Leverkusen, Germany) were provided by the manufacturers. The MICs and IC 50 s of ciprofloxacin, sparfloxacin and moxifloxacin were determined for all S. aureus strains, as described by Neyfakh et al. 3 and Markham & Neyfakh 5 by using microdilution plates containing two-fold serial dilutions of the antibacterial drugs in 100 L of LB medium (with an inoculum of 2 10 5 logorithmic-phase cells, and incubation for 12 h at 37°C). All experiments were carried out four times, with or without reserpine (20 mg/L). After the incubation period bacterial growth was assessed by observing the turbidity of the medium. IC 50 values were obtained as described by Soothill et al. 8 For each isolate tested, an MIC ratio and an IC 50 ratio were calculated by dividing the values obtained in the absence of reserpine by those obtained in the presence of reserpine.
PCR and sequencing
Protocols for the amplification and subsequent sequencing of grlA, grlB, gyrA, gyrB and norA have been described previously.
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Results and discussion
The presence of reserpine (20 mg/L), which by itself did not affect the growth of S. aureus (data not shown), 3, 5 in the incubation medium resulted in up to four-fold decreases in ciprofloxacin MICs and up to eight-fold decreases in the corresponding IC 50 values (Table I) . However, for 54 of the 102 strains tested, reserpine had no effect on the MIC or IC 50 values, resulting in MIC and IC 50 ratios of 1 for these strains. There could be several possible explanations for this. Strains could vary in the extent to which reserpine is able to block NorA or other efflux transporters because of reserpine resistance, as has been reported for Bmr, a related transporter in Bacillus subtilis. 10 Reserpine could also have varying effects because the expression of NorA and/or other as yet unidentified efflux transporters could vary as a result of regulatory mutations in the region upstream of norA or of the genes for other reserpine-sensitive transporters or may be localized to other regions of the chromosome, as appears to be the case for a previously reported inducible mutant. 2 The response to reserpine and the reduction in susceptibility did not correlate with the determined MIC and IC 50 values in the absence of reserpine or with mutations within the grl or gyr gene loci. Furthermore, the observed inhibitory effect was not dependent on fluoroquinolone susceptibility (Table I ). The effect of reserpine is independent of mutations within the coding and promoter regions of norA. In a previous study we sequenced 42 of the 102 MRSA isolates included in this study, of which six had different mutations within the norA promoter region as well as three isolates with different silent mutations within the protein-encoding region. 9 Additionally, in 14 fluoroquinolone-resistant isolates there was a Glu291 Asp mutation in the coding region of NorA. 9 There was no difference in the effect of reserpine on MIC and IC 50 values for these isolates compared with isolates wild-type for norA (data not shown). Thus reserpine as an inhibitor of multi-drug efflux pumps seems to increase the intracellular concentration of fluoroquinolones in some, but not all strains. This inhibition seems not to be determined by mutations detected within the grlA, grlB, gyrA, gyrB and norA gene loci.
In contrast to the effects of reserpine on ciprofloxacin MIC ratios and IC 50 ratios, the effects of reserpine on moxifloxacin MIC and IC 50 ratios (MIC ratio, 1-2; IC 50 ratio, 1-2) and sparfloxacin MIC and IC 50 ratios (MIC ratio, 1-2; IC 50 ratio, 1-2) were negligible (Tables II and Table I 
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III). Our data show that reserpine slightly decreased the MIC and IC 50 values of moxifloxacin or sparfloxacin for 21/102 and 11/102 strains, respectively. Thus our data suggest that, in some isolates, moxifloxacin and sparfloxacin are partly excreted by efflux transporters.
Differences in MIC and IC 50 values, with or without reserpine, between the drugs may result from differences in their chemical structure. Some authors have suggested that only hydrophilic quinolones (such as norfloxacin and ciprofloxacin), but not hydrophobic ones (such as sparfloxacin), may be excreted via an efflux pump. [2] [3] [4] [5] Fluoroquinolone-efflux systems, such as NorA, seem to be highly stable as the MIC and IC 50 values and ratios for each of the fluoroquinolones tested remained constant in clonally-related MRSA (Table IV) . In addition, the genetic stability of gene loci involved in quinolone resistance was shown by virtue of the fact that all 25 MRSA isolated during a 3 year period remained identical both phenotypically and genotypically, with respect to quinolone susceptibility (Table IV) .
In conclusion, reserpine reduced the ciprofloxacin MIC and IC 5 0 values for some strains, whilst for others it had no such effect. Differences did not correlate either with the determined MIC and IC 5 0 values in the absence of reserpine, or with mutations within g r l, g y r and n o r A g e n e loci. It is likely that efflux pump activity, like NorA, functions in all strains, albeit at variable levels. 2 -4 T h e reasons for these differences are not known, although varying rates of transcription of the n o r gene or differences in the stability of its mRNA may be responsible. Preliminary Northern analyses have shown the transcription rates in ten strains where reserpine had no effect on fluoroquinolone MICs were significantly lower than in ten strains where reserpine was able to decrease the MIC and I C 5 0 values by up to four-to eight-fold. Reserpine has more of an inhibitory effect on hydrophilic flu o r o q u i n o l o n e s , such as ciprofloxacin. Thus the clinical efficiency of such compounds against S. aureus may be improved in some strains, especially in those overexpressing NorA, by supplementing their use with a NorA inhibitor. a The Ser80 Phe mutation in the grlA gene, the Ser84 Leu mutation in the gyrA gene and the Gly291 Asp mutation in the norA gene combined with no mutation within the grlB and gyrB genes are present in all MRSA isolates belonging to PFGE type 1.
